Mineralys Therapeutics to Participate in Three Upcoming Conferences
November 09 2023 - 4:05PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD) and other diseases
driven by abnormally elevated aldosterone, today announced that
members of the senior management will be participating in the
Stifel Healthcare Conference being held in New York on November
14-15, the Jefferies London Healthcare Conference being held in
London on November 14-16, and the Evercore ISI 6th Annual
HealthCONx Conference being held in Miami on November 28-30.
| Stifel Healthcare Conference: |
|
Date: |
Wednesday,
November 15, 2023 |
| Time: |
12:40pm EST |
| Format: |
Fireside Chat |
| |
|
| Jefferies London Healthcare
Conference: |
| Date: |
Thursday, November 16, 2023 |
| Time: |
10:30am GMT |
| Format: |
Corporate Presentation |
| Webcast: |
Link |
| |
|
| Evercore ISI 6th
Annual HealthCONx Conference: |
| Date: |
Wednesday, November 29, 2023 |
| Time: |
11:15am EST |
| Format: |
Fireside Chat |
| Webcast: |
Link |
A live webcast of the presentation and fireside chat can be
accessed under “News and Events” on the Investor Relations section
of the Mineralys website at www.mineralystx.com. A replay of the
webcasts will be available on the Company’s website for
approximately 90 days.
About Mineralys TherapeuticsMineralys
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing medicines to target hypertension, CKD and other
diseases driven by abnormally elevated aldosterone. Its initial
product candidate, lorundrostat, is a proprietary, orally
administered, highly selective aldosterone synthase inhibitor that
Mineralys Therapeutics is developing for cardiorenal conditions
affected by abnormally elevated aldosterone, including hypertension
and CKD. Mineralys is based in Radnor, Pennsylvania, and was
founded by Catalys Pacific. For more information, please visit
https://mineralystx.com. Follow Mineralys on LinkedIn and
Twitter.
Contact:Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir Health Public
RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Apr 2024 to May 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From May 2023 to May 2024
